Saturday, October 10, 2020 3:39:26 PM
While looking into Regn-cov2 I keep finding talk like this. No firm explanations with round-about denials of the use of aborted fetuses' stem cells.
We can guess that R-cov2 will be extremely more expensive than Rem. Both seem hard to manufacture with questionable ingredients. Both have ethics issues. Both have limited access and incomplete Trials... Dexa*.?.
Average Covid infected patients don't receive care as early as Mr. T did. Most would only get one experimental drug at a time. Most insurance companies balk at even ONE experimental drug and then patients need to have strong Doctor support to just JOIN a Trial, then submit to their Ins-co. All this takes TIME Covid patients can't waste.
Apparently the early attacking Covid is working better than reactionary Treatments...Just some opinions...
https://www.usatoday.com/story/news/factcheck/2020/10/08/fact-check-trumps-antibody-therapy-not-made-fetal-stem-cells/5901542002/
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM